(Q42991390)

12 November 2017

Characteristics of antibody responses in tick-borne encephalitis vaccination breakthroughs (English)

1 reference

12 November 2017

1 reference

tick-borne encephalitis

1 reference

1

Karin Stiasny

1 reference

12 November 2017

Heidemarie Holzmann

2

1 reference

PubMed ID

19789092

12 November 2017

Franz X Heinz

series ordinal

3

1 reference

PubMed ID

19789092

12 November 2017

language of work or name

English

0 references

publication date

27 September 2009

1 reference

12 November 2017

1 reference

12 November 2017

27

1 reference

12 November 2017

50

1 reference

12 November 2017

7021-7026

1 reference

Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines

12 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

Hepatitis B vaccine -- do we need boosters?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

Field effectiveness of vaccination against tick-borne encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

Sequence analysis and genetic classification of tick-borne encephalitis viruses from Europe and Asia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

7 January 2021

Tick-borne encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

Tick-borne encephalitis--pathogenesis, clinical course and long-term follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

Diagnosis of tick-borne encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

Intrathecal IgM, IgA and IgG antibody response in tick-borne encephalitis. Long-term follow-up related to clinical course and outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

Laboratory findings in tick-borne encephalitis--correlation with clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

TBE vaccination and the Austrian experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

Two severe cases of tick-borne encephalitis despite complete active vaccination--the significance of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

Delayed humoral immunity in a patient with severe tick-borne encephalitis after complete active vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

Tick-borne encephalitis after active immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

Sequence of the structural proteins of tick-borne encephalitis virus (Western subtype) and comparative analysis with other flaviviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

Genome sequence of tick-borne encephalitis virus (Western subtype) and comparative analysis of nonstructural proteins with other flaviviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

Homogeneity of the Structural Glycoprotein from European Isolates of Tick-borne Encephalitis Virus: Comparison with Other Flaviviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

Detectability of IgM antibodies against TBE virus after natural infection and after vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

Cryptic Properties of a Cluster of Dominant Flavivirus Cross-Reactive Antigenic Sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 São Paulo epidemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

Mumps outbreak in a highly vaccinated school population: assessment of secondary vaccine failure using IgG avidity measurements.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

The importance of tick-borne encephalitis virus RNA detection for early differential diagnosis of tick-borne encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

Protective 'immunity' by pre-existent neutralizing antibody titers and preactivated T cells but not by so-called 'immunological memory'.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.069

10.1016/J.VACCINE.2009.09.069

7 January 2021

Identifiers

DOI

1 reference

12 November 2017

1 reference

PubMed ID

19789092